Issue 81, 2018

Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database

Abstract

We report herein the identification of urea structure-like small molecules by structure-based virtual screening of 10.5 million compounds. Based on a variety of HEK-Blue hTLRs reporter cell assay results, we validated a TLR1/2-specific small molecule agonist, ZINC666243 (SMU127), with EC50 of 0.55 ± 0.01 μM. SMU127 stimulates NF-κB activation and promotes TNFα secretion in human macrophages and mononuclear cells. Moreover, the in vivo assay indicated that SMU127 could inhibit the growth of breast cancer tumors in BABL/c mice. This work has shown for the first time that a small molecule TLR1/2 agonist can inhibit breast cancer in vivo.

Graphical abstract: Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database

Supplementary files

Article information

Article type
Communication
Submitted
14 Aug 2018
Accepted
17 Sep 2018
First published
18 Sep 2018

Chem. Commun., 2018,54, 11411-11414

Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database

Z. Chen, X. Cen, J. Yang, X. Tang, K. Cui and K. Cheng, Chem. Commun., 2018, 54, 11411 DOI: 10.1039/C8CC06618C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements